This randomized Phase II-III trial sought to evaluate the efficacy and safety of adding bevacizumab (Bev) following induction chemotherapy (CT) in extensive small-cell lung cancer (SCLC). Administering 7.5mg/kg Bev after induction did not improve outcome in extensive SCLC patients.

READ FULL ARTICLE Curated publisher From Mdlinx